TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female study subjects must be adults (≥ 6 years of age)~* Confirmed diagnosis of CF~* History of chronic infection with P.aeruginosa~* FEV1 ≥40% of predicted at Screening~* Ability to comply with study medication use, study visits and procedures~* Ability to produce 0.5 grams of sputum~Key Exclusion Criteria:~* Administration of any investigational drug within 8 weeks to Study Day 1~* Emergency room visit or hospitalization for CF or respiratory-related illness within 4 weeks prior to screening~* History of alcohol, medication or illicit drug abuse within 1 yr. to screening~* History of lung transplantation~* Female of childbearing potential who are not practicing an acceptable method of birth control or who are lactating~* Positive Pregnancy test~* Use of any anti-pseudomonal antibiotics within 28 days prior to Study Day 1~* Initiation of chronic therapy within 28 days prior to Study Day 1~* History of sputum or throat swab culture yielding Burkholderia cepacia within 2 years prior to screening~* History of mycobacterial and/or Aspergillus infection requiring treatment within 2 years prior to screening~* History of biliary cirrhosis with portal hypertension, or splenomegaly

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Arikayce™ at 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
- B (Type: PLACEBO_COMPARATOR): Matching placebo for 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
- C (Type: ACTIVE_COMPARATOR): Arikayce™ at 70 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
- D (Type: ACTIVE_COMPARATOR): Arikayce™ at 140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
- E (Type: PLACEBO_COMPARATOR): Matching placebo for 70 mg/140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing HIV Risk Among Adolescents: Evaluating Project HEART

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 10th grade girl~* Able to read English~Exclusion Criteria:~* None

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Project HEART (Type: EXPERIMENTAL): Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
- Control: Project Growing Minds (Type: OTHER): Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with CD20 and CD22-positive, follicular or diffuse large B-cell NHL who have not responded or progressed after 1 or 2 prior therapies; or subjects with CD20 and CD22-positive intermediate/aggressive NHL (diffuse large B-cell, mantle cell, transformed follicular or follicular grade 3b NHL) who have not responded or progressed after 1 or more prior therapies and are refractory to a previous rituximab containing therapy.~* Prior therapy must contain at least one course of rituximab therapy, as single agent or in combination.~* Measurable disease.~Exclusion Criteria:~* Subjects who are candidates for other potentially curative therapies.~* Subjects must not have received previous radioimmunotherapy.~* Subjects who have undergone a prior bone marrow transplantation within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (FOLLICULAR) (Type: EXPERIMENTAL): Follicular
- INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (DLBCL) (Type: EXPERIMENTAL): Diffuse Large B-cell Lymphoma
- INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (REFRACTORY) (Type: EXPERIMENTAL): Refractory Aggressive NHL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Economic Analysis of Demand for Marijuana

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* marijuana use at least 8 times in the past month on average and at least monthly for the past 6 months~* English-speaking~* negative urine toxicology screen for drugs other than marijuana~* non-treatment seeking~* purchase of marijuana at least twice in the past 6 months to confirm familiarity with the construct to be measured~Exclusion Criteria:~* positive pregnancy test~* nursing~* inability to use contraception during the study~* poor physical health~* positive breath alcohol concentration~* diagnosis of a current affective disorder, psychosis, and panic disorder~* self-report of past serious adverse reaction to marijuana~* current psychotropic drug use~* smoking more than 20 tobacco cigarettes per day~* inability to abstain from marijuana for 15 hours~* body mass index outside 18.5-30 kg/m2 range

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- High THC dose (6% THC) (Type: EXPERIMENTAL): Smoked marijuana cigarettes (High THC dose \[6% THC\])

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Shared Decision Making to Improve Palliative Care in the Nursing Home

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Residents: Residents of The Bluffs nursing home, Columbia Missouri, over the age of 65, have at least one family member who agrees to participate, and have a serious life limiting illness. Residents enrolled in hospice or admitted to post hospital short term nursing home stay are excluded from participation.~* Family Members: Identified family member by a resident or nursing home staff at The Bluffs, over the age of 18, without cognitive impairment, and with access to a computer, tablet, or smartphone device.~Exclusion Criteria:~* Residents enrolled in hospice can not participate.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): These family members and residents will use web conferencing technology to attend their quarterly care conferences
- Control (Type: NO_INTERVENTION): These family and residents will receive usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Neuroprotective Effects of Dexmedetomidine During Brain Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing elective craniotomy for supratentorial brain tumor resection or cerebral vascular surgery~* age between 20 to 80 yr~Exclusion Criteria:~* Fever, elevated white blood cell or C-reactive protein~* Impaired liver function, eg. AST or ALT \>100; liver cirrhosis \> Child B class~* Impaired renal function, cGFR\< 60 ml/min/1.73 m2~* Cardiac dysfunction, such as heart failure \> NYHA class II

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DEX (Type: EXPERIMENTAL): Intraoperative intravenous infusion of dexmedetomidine
- Control (Type: PLACEBO_COMPARATOR): Intraoperative intravenous infusion of 0.9% saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Acute deep vein thrombosis (DVT) of the leg involving proximal veins, and/or pulmonary embolism (PE) iin patients for whom at least 6 months of anticoagulant therapy is considered appropriate~2. Male or female, being 18 years of age or older~3. Written informed consent for study participation~Exclusion criteria~1. Overt symptoms of VTE for longer than 2 weeks prior to enrolment~2. PE satisfying at least one of the following criteria: Haemodynamic instability, embolectomy is indicated or performed, thrombolytic therapy is indicated or performed, or suspected source of PE is other than the legs~3. Actual or anticipated use of vena cava filter~4. Contraindications to anticoagulant therapy~5. Patients who in the investigators opinion should not be treated with warfarin~6. Allergy to heparins or other alternate approved therapy used for initial treatment, warfarin or dabigatran, or to one of the excipients included in these medications~7. Patients who in the investigators judgement are perceived as having an excessive risk of bleeding~8. Known anaemia~9. Need of anticoagulant treatment for disorders other than VTE~10. Recent unstable cardiovascular disease~11. Elevated AST or ALT \> 2x ULN~12. Liver disease expected to have any potential impact on survival~13. Patients who have developed transaminase elevations upon exposure to ximelagatran~14. Severe renal impairment~15. Women who are pregnant, nursing, or of childbearing potential who refuse to use a medically acceptable form of contraception~16. Participation in another clinical trial with an investigational drug during the last 30 days or previous participation in this study~17. Patients considered unsuitable for inclusion by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dabigatran etexilate 150 mg (Type: EXPERIMENTAL): twice daily
- warfarin (INR 2-3) (Type: ACTIVE_COMPARATOR): prn to maintain INR (2-3)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Each of the following criteria must be fulfilled for a subject to be eligible:~1. Age ≥ 18 years~2. OHCA of a presumed cardiac cause~3. Unconsciousness upon admission, i.e. a GCS \< 9~4. Sustained ROSC for more than 20 minutes~Exclusion Criteria:~None of the following criteria must be fulfilled for a subject to be eligible:~1. Consciousness upon admission, i.e. a GCS ≥ 9~2. Presumed non-cardiac cause of arrest~3. Unwitnessed asystole~4. Suspected or confirmed intracranial bleeding or stroke~5. Pregnancy, or females in fertile age, unless a negative serum HCG can rule out pregnancy within the inclusion window.~6. Temperature on admission \< 30 °C~7. Persistent cardiogenic shock\* that is not reversed within the inclusion window~8. Known disease making 180 day survival unlikely~9. Known limitations in therapy~10. Known pre-arrest Cerebral Performance Category of 3 to 4~11. \> 240 minutes from ROSC to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: ACTIVE_COMPARATOR): A one hour infusion of a single 8mg/kg dose (max. 800mg) of tocilizumab to attenuate systemic inflammation after out-of-hospital cardiac arrest, given as early as possible after hospital admission.
- Isotonic saline (Type: PLACEBO_COMPARATOR): A one hour infusion of isotonic saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Healthy adults 18 to 45 years of age who were seronegative for HBsAg, anti-HBs, anti-Hepatitis B core antigen, HIV, and Hepatitis C Virus (HCV)~Exclusion Criteria:~* Evidence of alcoholism or drug abuse, history of HIV, or HCV~* Blood transfusions within the three months prior to inclusion in the study~* Uncontrolled hypertension and other cardiovascular diseases~* Chronic/concurrent administration (\>14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. Inhaled and topical steroids were permitted~* History of anaphylaxis (including shock) or any significant allergy or atopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Sci-B-Vac-SciGen (Type: EXPERIMENTAL): The 3-antigen HepB vaccine, Sci-B-Vac-SciGen (SciGen Israel Ltd., produced in a new production facility located in Rehovot, Israel) contains three recombinant proteins of hepatitis B virus (HBV) envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-SciGen was supplied in a final volume of 1.2 ml vials
- Engerix-B (Type: ACTIVE_COMPARATOR): The single antigen HepB vaccine, Engerix-B (GSK), contains the small S recombinant protein. Engerix-B was supplied in 1.0 ml vials.
- Sci-B-Vac-BTG (Type: EXPERIMENTAL): The 3-antigen HepB vaccine, Sci-B-Vac-BTG (Bio-Technology General (BTG) Ltd., Rehovot, Israel.) contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-BTG was supplied in a final volume of 1.2 ml vials

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily provide written informed consent prior to the conduct of any study related procedures~* Male or female, 18-65 years of age~* Meet DSM-IV criteria for current opioid dependence~* Females of childbearing potential and fertile males must use a reliable means of contraception~Exclusion Criteria:~* Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS)~* Presence of aspartate aminotransferase (AST) levels ≥ 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels ≥ 3 X upper limit of normal and/or total bilirubin ≥ 1.5 X upper limit of normal and/or creatinine ≥ 1.5 X upper limit of normal~* Received treatment for opioid dependence (e.g., methadone, BPN), within the previous 90 days~* Current diagnosis of chronic pain requiring opioids for treatment~* Candidates for only short term opioid treatment or opioid detoxification therapy~* Pregnant or lactating females~* Previous hypersensitivity or allergy to BPN- or EVA-containing substances or naloxone~* Current use of agents metabolized through CYP 3A4 such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)~* Current anti-coagulant therapy (such as warfarin) or an INR \> 1.2~* Meet DSM-IV criteria for current dependence on any other psychoactive substances other than opioids or nicotine (e.g., alcohol, sedatives)~* Current use of benzodiazepines other than physician prescribed use~* Significant medical or psychiatric symptoms or dementia which in the opinion of the Investigators would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent~* Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in study~* Participated in a clinical study within the previous 8 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): None
- Group B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Different Volumes of Local Anesthetics in Thoracolumbar Interfascial Plane Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ● Both gender~  * Type of surgery: lumbar spine surgeries involving 1 up to 3 adjacent lumbar vertebrae~ * Physical status ASA I, II.~ * Age 18 to 65 Years.~ * Body mass index (BMI): \> 20 kg/m2 and \< 35 kg/m2.~Exclusion Criteria:~* ● Patients on preoperative opioid regimen for more than 1 month.~  * Patients with history of previous surgical operations in the lumbar region.~ * Patients with spinal deformities (eg. Scoliosis.....).~ * Hypersensitivity to Bupivacaine.~ * Extensive Lumbar spine surgeries like large tumor excisions, scoliosis correction or more than 2 level spine fixations.~ * Patients with communication difficulties.~ * Lumbar spine operations that will be performed with the patient in any position other than the prone position.~ * Severe neurological compromise (severe muscle weakness such as foot drop or sphincter disorders such as urinary incontinence).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- mTLIP10 (Type: EXPERIMENTAL): patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 20 ml 0.25%bupivacaine (10 ml on each side).
- mTLIP20 (Type: EXPERIMENTAL): patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 40 ml 0.25%bupivacaine (20 ml on each side).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Epidural Stimulation on Muscle Activation and Sensory Perception

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Research Inclusion Criteria~* Subjects diagnosed with CLBLP by a pain specialist with a documented referral for evaluation of SCS surgery by the pain specialist~* Subjects with the ability to walk~* Age 18-80~Research Exclusion Criteria~* Subjects with the inability to consent for themselves.~* Prior history of spinal neoplasm, infection, arteriovenous malformation and/or radiation to the spine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Epidural Spinal Cord Stimulation (Type: EXPERIMENTAL): Subjects with chronic pain that have been scheduled to receive spinal cord simulators for standard of care treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete